China Pharmaceutical is not a traitorous enterprise. (hereinafter referred to as Sinopharm) is the State Council State-owned Assets Supervision and Administration Commission management China Pharmaceutical Group of the pharmaceutical and health industry group China Pharmaceutical Group, holds the certificate of the enterprise group issued by the State Market Supervision and Administration Department China Pharmaceutical Group, belongs to the State-owned enterprises can not be traitorous enterprises. China Pharmaceutical Group Limited, or China Pharmaceutical Group, is China's largest, most complete industrial chain, the strongest comprehensive strength of the pharmaceutical and health industry group directly managed by the State-owned Assets Supervision and Administration Commission of the State Council.
Is China Pharmaceutical Group a state-owned enterprise or a centralized enterprise?China Pharmaceutical is a centralized enterprise. State Pharmaceutical Group China Pharmaceutical Group, that is, China Pharmaceutical Group Limited China Pharmaceutical Group, is a state-controlled enterprise directly managed by the central government China Pharmaceutical Group. Founded on March 26, 1987 China Pharmaceutical Group, China Pharmaceutical Group Limited is headquartered in Haidian District, Beijing, and its legal representative is Liu Jingzhen.
In the Directory of Central Enterprises released by the State-owned Assets Supervision and Administration Commission of the State Council (SASAC) on November 8, 2019, China Pharmaceutical Group Limited is at number 78 in the Directory of Central Enterprises. Shareholders of China Pharmaceutical Group Limited: the State Development and Investment Group Limited, the State-owned Assets Supervision and Administration Commission of the State Council, and China Guoxin Holdings Limited.
Definition of centralized enterprises.
Central enterprises, short for "centrally managed enterprises", refers to the central people's government (state council) or entrusted state-owned assets supervision and management agency to exercise the responsibilities of the funder, the leadership team by the central government directly or entrusted to the central organization department, the state council state-owned assets supervision and management commission or other central ministries and departments of the central government, the state council state-owned assets supervision and management commission or other central ministries and departments of the central government. other and other central ministries (associations) management of wholly state-owned or state-controlled enterprises.
In accordance with the division of state-owned assets management authority, state-owned enterprises are divided into central enterprises (state-owned enterprises supervised and managed by the central government) and local enterprises (state-owned enterprises supervised and managed by local governments). Central enterprises occupy a dominant position in major industries and key areas that are related to national security and the lifeblood of the national economy, and are important pillars of the national economy.
What is the relationship between the two listed companies, Sinopharm and Sinopharm?The two as listed companies have no relationship, but the controlling shareholders of the two are enterprises under the State-owned Assets Supervision and Administration Commission (SASAC) Sinopharm's controlling shareholder is Sinopharm Holding, and China Pharmaceutical's controlling shareholder is China General Technology
Information Expanded
Sinopharm Pharmaceutical Group Pharmaceutical Company Limited was initiated by the China National Pharmaceutical Group Corporation, and approved by the State Economic and Trade Commission (SETAC) and formally established on December 21, 1999, the company was founded. It was formally established on December 21, 1999 with the approval of the State Economic and Trade Commission. The business scope of Sinopharm includes: organizing the production of pharmaceuticals; sales of chemical raw materials, western pharmaceutical preparations, biochemical drugs, biological products and proprietary Chinese medicines; self-supporting and acting as an agent for the import and export business of all kinds of commodities and technologies; import processing and "three to one subsidy" business; countertrade and re-export trade; the sale of health food and consulting related to the above business. Consultation.On February 18, 2016, Sinopharm announced the suspension of trading; on February 25, Sinopharm released the Announcement on the Extension of the Actual Controller to Fulfill the Relevant Commitments, in which Sinopharm intends to extend the fulfillment of the relevant commitments, and extend the deadline for the completion of the commitments from the original March 11, 2016, to March 11, 2017.
Chinopharm is a member of the China National Pharmaceutical Group (Sinopharm), which is a wholly owned subsidiary of Sinopharm. Difference between China National Pharmaceutical Group and China Pharmaceutical GroupIt is not a company, Sinopharm belongs to Sinopharm's listed company, which is one of its subsidiaries. Sinopharm is known as Sinopharm Pharmaceutical Group Pharmaceutical Company Limited, formerly known as China Pharmaceutical Company, in December 21, 1999 by the China Pharmaceutical Group Corporation initiated and established, in 2002 in the Shanghai Stock Exchange successfully listed.
Expanded Information:
China Pharmaceutical Group is a centralized enterprise.
China Pharmaceutical Group Corporation, or China Pharmaceutical Group, is China's largest pharmaceutical and health industry group with the most complete industrial chain and the strongest comprehensive strength, which is directly managed by the State-owned Assets Supervision and Administration Commission of the State Council. It is mainly engaged in the distribution, retailing, research and development, and production of health-related products such as preventive treatment and diagnostic care.
Pharmaceutical Group has a pharmaceutical distribution network covering 31 provinces, autonomous regions and municipalities directly under the central government and 30 distribution centers that are on par with international standards. It is the largest biomedical R&D and production enterprise in China, and undertakes the production of more than 80% of vaccines for national immunization planning.
Expanded Information:
China Pharmaceutical Group has set up production bases for biopharmaceuticals, narcotic and psychotropic drugs, anti-infectives, anti-tumor drugs, cardio-cerebral and cerebral vascular drugs, and respiratory drugs, and medicinal materials, and has also passed the certification of the U.S. FDA, EU, and WHO pre-certification.
One of them is a biopharmaceutical R&D and production enterprise, which can produce all vaccine varieties for China's legal immunization program, and undertakes the production of more than 80% of vaccines for the national immunization program, as well as being the sixth-ranked vaccine supplier in the world.
China Pharmaceutical Group has built a complete Chinese medicine health industry chain including cultivation, scientific research, production and sales of Chinese medicines, and produces more than 900 proprietary pharmaceutical products, 15 old Chinese brands and four intangible cultural heritage products, which enable traditional Chinese medicine to flourish.
China Pharmaceutical Group has cultivated 26 exhibition brands such as China International Medical Device Expo, covering the entire human health industry chain and various sub-fields, and become a platform for cooperation and exchange in China's pharmaceutical and healthcare fields, driving the development of the entire pharmaceutical industry.
China Pharmaceutical Group has successfully explored the new model of "Big Health Concept Store", and formed a new group of stores, including "Guoda", "Golden Elephant", "Dade Sang", and "Dai De Sheng", "Dadexiang", "Tianyitang" and other brands, and has set up more than 4,500 retail pharmacy chains.
It has established a medical service network, forming several regional medical clusters in Henan, Hubei and Liaoning, with 23 medical institutions including three tertiary hospitals and six secondary hospitals, with a total of nearly 10,000 beds, so that more people can enjoy convenient medical and health services.
China Pharmaceutical Group has established 26 joint ventures with internationally renowned pharmaceutical companies, conducted trade with more than 60 countries along the Belt and Road, and established trade relations with more than 120 countries and regions in the world, further expanding cooperation channels.
The live encephalitis B vaccine with independent intellectual property rights became the first vaccine product in China to pass the pre-certification of the World Health Organization and was included in the procurement of United Nations agencies, from which the whole world benefited. We have established overseas industrial bases in Vietnam and Malaysia, and assisted in the construction of hospitals and mobile clinics in Myanmar and Cambodia, making positive contributions to our social responsibilities such as enhancing the health and well-being of local people and promoting employment.
Reference:
Sinopharm Sinopharm Pharmaceutical Group Pharmaceutical Company Limited was initiated and established by China Pharmaceutical Group Corporation China Pharmaceutical Group, approved by the State Economic and Trade Commission China Pharmaceutical Group, was formally established on December 21, 1999, Sinopharm adheres to the glorious tradition of its predecessor, China National Pharmaceutical Company, for more than half a century, shouldering the people's public prevention of disease and treatment of disease, rehabilitation and health care, first aid in disaster and epidemic and the central reserve, and other sacred mission, in order to protect the public's The company has made unremitting efforts to safeguard the life and health of the public. Ltd. is the largest pharmaceutical and health industry group in China with the most complete industrial chain and the strongest comprehensive strength, which is directly managed by the State-owned Assets Supervision and Administration Commission of the State Council.